Egalet to Present at Upcoming Conferences in February

WAYNE, Pa., Feb. 2, 2015 /CNW/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a specialty pharmaceutical company focused on developing and commercializing effective pain medications while delivering peace of mind to physicians and patients, today announced that Bob Radie, president and chief executive officer, will present at upcoming conferences:

Virtual Investor Conferences
Date and Time: Thursday, February 5, 2015 at 1:00 PM EST
Webcast: http://VirtualInvestorConferences.com

17th Annual BIO CEO & Investor Conference
Date and Time: Monday, February 9 at 5:30 PM EST
Webcast: http://egalet.investorroom.com/

About Egalet
Egalet, a fully integrated commercial specialty pharmaceutical company, is focused on developing, manufacturing and marketing innovative pain treatments. The Company has two approved products: OXAYDO (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where an opioid is appropriate, and SPRIX® (ketorolac tromethamine) Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID), indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. In addition, using Egalet's proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full prescribing information for OXAYDO and SPRIX and additional information on Egalet can be found at www.egalet.com

SOURCE Egalet Corporation

For further information: Investor and Media: E. Blair Clark-Schoeb, Senior Vice President, Communications, Email: bcs@egalet.com, Tel: 917-432-9275, http://www.egalet.com

Organization Profile

Egalet Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890